Loading data for ELDN — first visit, this takes a few seconds.

Alerta

Eledon Pharmaceuticals In... (ELDN)

NasdaqCM: ELDN · Precio en tiempo real · USD

3.29

-0.06 (-1.79%)

Al cierre: Aug 27, 2026, 3:59 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

-1.79% (1D)

Precio de compra	2.4
Capitalización de mercado	266.13M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-98.56M
	0.96
	-0.9
	n/a
	-4.25
P/B (TTM)	3.68
P/S (TTM)	n/a
Fecha de resultados	Nov 13, 2026

Precio de venta	4.18
Volumen	570,162
Volumen medio (20D)	1,260,911
Abierto	3.42
Anterior Cerrar	3.35
Rango del día	3.25 - 3.42
Rango de 52 semanas	1.35 - 4.60
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ELDN

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic po...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Sep 17, 2014

Empleados 33

Bolsa de Valores NasdaqCM

Símbolo bursátil ELDN

Sitio web https://eledon.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Eledon Pharmaceuticals fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -45.62M, un aumento de 26.07%.

Estados financieros

Sorpresa de resultados

Eledon Pharmaceuticals ha publicado sus resultados trimestrales en Aug 13, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
EPS de -0.27 falla las estimaciones por -0.12, con -107.69% Disminución interanual.

Próxima publicación de resultados

Está previsto que Eledon Pharmaceuticals Inc. publique sus resultados el Nov 13, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

2 meses hace · Zacks

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?

Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.

2 meses hace · Insider Monkey

Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart

While Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has gained 125.83% year-to-date, analysts continue to see 134.60% upside, helping it secure a spot on our list of the hot biotech stocks under $5 to bu...

3 meses hace · Zacks

Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?

Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

3 meses hace · Benzinga

EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug

NewcelX Ltd. reported its 2025 financial results, with leadership emphasizing a "transformative year" marked by merger completion, balance sheet improvements, and progress in its lead Type 1 diabetes ...

4 meses hace · Insider Monkey

Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the 10 Unstoppable Stocks That Could Double Your Money. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the unstoppable stocks that could double...

Página 1 de 2